Celgene Corp (NASDAQ:CELG)

99.37
Delayed Data
As of Sep 20
 +0.42 / +0.42%
Today’s Change
58.59
Today|||52-Week Range
99.66
+55.05%
Year-to-Date
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
Sep 20 / Zacks.com - Paid Partner Content
Amgen's Kyprolis Combo Improves PFS in Multiple Myeloma Study
Sep 16 / Zacks.com - Paid Partner Content
3 Big Biotech Stocks Worth Adding to Your Portfolio Now
Sep 20 / Zacks.com - Paid Partner Content
Celgene's (CELG) Leukemia Candidate Meets Endpoints in Study
Sep 13 / Zacks.com - Paid Partner Content
Biotech Stock Roundup: BIIB Halts AD Study, AMGN Posts Positive MM Drug Data & More
Sep 18 / Zacks.com - Paid Partner Content
J&J's Ponesimod Superior to Aubagio in Relapsing MS Patients
Sep 12 / Zacks.com - Paid Partner Content
Acceleron Discontinues Mid-Stage Muscular Dystrophy Study
Sep 18 / Zacks.com - Paid Partner Content
Celgene (CELG) Outpaces Stock Market Gains: What You Should Know
Sep 11 / Zacks.com - Paid Partner Content
Celgene (CELG) Gains But Lags Market: What You Should Know
Sep 17 / Zacks.com - Paid Partner Content
FDA Grants Orphan Drug Status to Acceleron's PAH Candidate
Sep 10 / Zacks.com - Paid Partner Content
Karyopharm Signs $150M Royalty Agreement to Support Xpovio
Sep 17 / Zacks.com - Paid Partner Content
Roche's Tecentriq Combo Gets EU Nod for Difficult Lung Cancer
Sep 06 / Zacks.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Celgene, Sinopec, HSBC, Vertex Pharmaceuticals and Prudential Financial
Sep 17 / Zacks.com - Paid Partner Content
Celgene (CELG) Gains But Lags Market: What You Should Know
Sep 05 / Zacks.com - Paid Partner Content
Top Stock Reports for Celgene, Sinopec & HSBC
Sep 16 / Zacks.com - Paid Partner Content